Background. CXCR4-using virus is associated with higher viral load and accelerated human immunodeficiency virus (HIV) disease progression. Additionally, CCR5 antagonists may not reduce the HIV-1 RNA load when mixed/ dual-tropic or CXCR4-using virus is present. The determination of coreceptor tropism may be required before CCR5 or CXCR4 antagonists are initiated, unless reliable predictive markers of coreceptor use are established.
HIV entry into cells involves several distinct steps: CD4 attachment, coreceptor interaction, and fusion. The binding of gp120 to CD4 exposes a binding site that enables gp120 to interact with a cell-surface chemokine receptor, generally CCR5 and/or CXCR4. This, in turn, induces conformational changes in gp41, activating the fusion process, bringing the viral and cell membranes in close apposition to facilitate fusion, and releasing the viral core into the cytoplasm. This understanding of the processes in HIV-1 entry into target cells has enabled efforts to develop drugs that target individual steps in this process. The first approved drug to target entry was enfuvirtide, an injectable peptide drug that blocks fusion [1] . Agents that bind gp120 inhibit attachment to CD4 or antagonize CCR5 or CXCR4 interactions have all reported short-term antiviral activity [2] .
CCR5 strains are generally found at the time of HIV-1 acquisition; the transmission of CXCR4 virus appears to be constrained [3] . Mixed populations or dual-tropic R5X4 and X4 strains have mostly been described in persons who have decreased CD4 cell counts [4] . Although individuals progress to AIDS in the absence of CXCR4-using variants, the appearance of these variants is strongly associated with both a rapid increase in viral load [5] and accelerated disease progression. It is uncertain whether the emergence of CXCR4-using variants is a cause or a consequence of immune destruction. Nevertheless, this association indicates an important role for CXCR4 usage in disease progression. Even when R5X4 or X4 variants arise in vivo, the R5 variants typically persist, so CCR5 remains a critical coreceptor throughout the course of HIV infection. Several related chemokine receptors support HIV-1 entry in vitro, but there is no evidence that any coreceptor other than CCR5 and CXCR4 is used in vivo or plays a role in pathogenesis. Coreceptor selectivity is determined by genetic sequences within gp120, particularly a highly variable and structurally flexible region termed "V3" [6] . Variation in coreceptor usage that is determined by viral clade has been suggested [7] .
The determination of coreceptor usage may have several clinical applications. Because the appearance of CXCR4-using virus is associated with an increase in viral load and accelerated disease progression, the presence of virus that uses this coreceptor may prompt the initiation of treatment. Additionally, anecdotal evidence suggests that the administration of a CCR5 antagonist may not lead to decreases in HIV-1 RNA loads when mixed, dual-tropic, or CXCR4-using virus is present [8] ; hence, screening may need to be performed before these drugs are administered, unless reliable predictive markers of coreceptor use are established.
Until recently, methods for determining viral coreceptor use were both slow and resource intensive. ViroLogic (San Francisco, CA) has developed a vector-based assay for the rapid phenotypic assessment of coreceptor usage through the use of technology based on their PhenoSense assay. Our objectives were to establish the prevalence of coreceptor use across a large group of persons with HIV and to establish the characteristics associated with and predictive of the presence of CCR5-using virus.
SUBJECTS AND METHODS

Study population. The Chelsea and Westminster Hospital in
London is the largest treatment center for HIV infection in the United Kingdom, treating ∼4500 persons with HIV infection. Immunologic, virologic, hematologic, and biochemical data are obtained from all patients every 3 months, together with information on antiretroviral therapy and concomitant medication. All tests, results, procedures, drug history, and clinicalevent data are routinely prospectively collected and maintained on our local database. Samples drawn for viral load and resistance testing are aliquoted, and back-up plasma samples are stored at Ϫ80ЊC. The routine collection of plasma samples began in 1996. The collection and use of samples was supervised by the Riverside Research Ethics committee and was performed according to standard operating procedures in place since 1996. To achieve our study objectives, we selected samples from both treatment-naive persons and those whose first treatment regimen failed. Samples were selected on the basis of the availability of a date-matched viral genotype (Virco NV), to provide information on any possible association with pol gene mutations and viral clade. Samples were also required to have a matched viral load of 11000 copies/mL, to ensure polymerase chain reaction amplification. The inclusion of 2 samples from the same individual was allowed as long as the samples were obtained during treatment-naive and -experienced states and 11 year apart. Samples were shipped to ViroLogic for processing.
Samples from subjects who met the above criteria and had a successful determination of coreceptor use phenotype by use of the Phenosense assay were used to construct the database. Characteristics of samples whose coreceptor phenotype could not be determined were also assessed, to confirm that the typed sample set was representative of the sampled population.
ViroLogic Phenosense assay. To perform the ViroLogic Phenosense assay, virus is first pelleted by centrifugation from plasma and disrupted by use of a lysis buffer. Viral RNA is extracted by use of oligo(dT) magnetic beads. After initial HIV cDNA strands were made, env-specific sequences were amplified by use of a thermostable DNA polymerase blend with forward and reverse primers that resulted in a 2.5-kb amplification product that spanned the entire open-reading frame of the HIV-1 gp160 protein. These samples' amplification products were digested, purified by agarose gel electrophoresis, and ligated into an expression vector. Escherichia coli organisms were transformed, and libraries of envelope sequences representative of the diversity of the viral quasi species were prepared.
A retroviral vector (pHIVluc) that is replication defective and contains a luciferase expression cassette inserted within a deleted region of the env gene was used to cotransfect human embryonic kidney cell cultures with the samples' envelope-expression plasmid DNA. Virus stocks were harvested 48 h after transfection and were used in the coreceptor tropism assay. The recombinant viruses were assessed for their ability to infect different cell types expressing CD4 and CCR5 or CXCR4 receptors in the presence or absence of specific receptor antagonists. Statistics. Logistic regression analysis was used to test for associations between tropism that were grouped by dichotomy of either R5 or R5X4 and X4 phenotype and identified explanatory variables. HIV-1 RNA load, CD4 cell count, CD4 cell percentage, CD8 cell count, CD8 cell percentage, CD19 cell count, natural killer (NK) cell count, and NK cell percentage were defined as those results that were available closest to the typed sample (usually from the same blood draw). Quantitative data were grouped into respective quartiles, where these were assumed to be unbiased cutoffs. In addition, grouped CD4 cell count and viral load were further assessed by use of arbitrary cutoff values that were considered by the lead clinicians (G.M. and B.G.) to be potentially clinically useful. The GENMOD procedure was used with the logit link function and binomial error distribution to perform univariate and multivariable logistic regression analyses. Those variables that were found to be significant ( ) were used to build the multivariable P ! .15 models. All data analyses were performed in SAS (version 8.02; SAS Institute), and all P values are 2-sided. Samples that failed to amplify were derived from patients with demographic and immunologic characteristics similar to those of the population in which samples were successfully evaluated. However, significant differences in viral characteristics were observed with regard to HIV-1 RNA load (median baseline HIV-1 RNA load, 12,793 copies/mL; range, 3784-51,666 RNA copies/mL in failed samples vs. median, 39,325 copies/mL; range, 11,557-129,015 copies/mL in typed samples;
RESULTS
A total of
) and non-clade B virus P ! .001 rates (20.4% of failed samples and 16.2% of typed samples).
Among the 53 paired samples, no changes in viral phenotype were observed between samples from treatment-naive and -experienced subjects (data not shown). For primary analysis and modeling purposes, only the treatment-naive sample from each of these pairs was included. This left a total study population of 563 individuals, 402 (71.4%) of whom were treatment naive and 161 (28.6%) of whom were treatment experienced at the time of sampling. No clade type was available for 45 samples. Of 518 samples with an available clade data, 18.6% of samples had non-clade B virus (most commonly clade C or A). Table 1 provides the demographic, immunologic, and virologic characteristics of the study population.
CXCR4 or mixed/dual tropic CCR5/CXCR4 virus was present in 112 (19.9%) of samples tested. Mixed/dual-tropic populations were most commonly observed, with only 4 (0.7%) samples showing "exclusive" CXCR4 use. Absolute CD4 cell count and percentage were significantly lower and HIV-1 RNA load significantly higher in individuals harboring CXCR4-using virus (table 1) . Associations with exposure to antiretroviral agents, the presence of reverse transcriptase, and protease gene mutations were not observed. Similarly, no association with viral clade was observed. In a univariate regression model (table  2) , higher absolute CD4 cell count, lower HIV-1 RNA load, and lower NK cell count (all by quartile) were associated with the presence of CCR5 usage. In the multivariate model (table  3) , these significant associations of CCR5 usage with higher CD4 cell count, lower NK cell count, and lower HIV-1 RNA load persisted. Similar outcomes were seen if only the treatment-naive population was evaluated and the CD4 cell count and viral load were distributed by arbitrary category (data not shown). Actuarial analysis of the risk of CCR5 use by CD4 cell count and viral load supported these associations. In persons with CD4 cell counts 1300 cells/mm 3 and HIV-1 RNA loads !5000 copies/mL, 42 (89%) of 47 of samples contained CCR5-using virus, whereas, for persons with CD4 cell counts !50 cells/mm 3 and HIV-1 RNA loads 1100,000 copies/mL, only 17 (55%) of 31 of samples contained CCR5-using virus. Data for intermediate CD4 cell count and HIV-1 RNA values generally fell between these values (data not shown).
DISCUSSION
We observed significant associations among CD4 cell count, HIV-1 RNA load, NK cell count, and chemokine coreceptor use. Associations between HIV-1 RNA load and CD4 cell count and coreceptor usage have been reported elsewhere, in smaller cohorts [4, 9, 10] . Although the risk of mixed/dual-tropic R5X4 virus or X4-using virus increased with decreasing CD4 cell counts and increasing HIV-1 RNA load, a high CD4 cell count (1300 cells/mm 3 ) and low viral load (!5000 copies/mL) did not exclude the presence of these viruses. These laboratory markers cannot, therefore, be used to predict the presence of CCR5-using virus in the clinical setting.
Coreceptor use has been established as a determinant of disease progression-individuals with virus using the CCR5 coreceptor generally have a slower rate of progression and lower viral load than those with virus using CXCR4. However, the possession of CCR5 virus does not prevent the progression of the CD4 cell decrease or clinical events. The development of CCR5 antagonists represents a new therapeutic advance that may require a reliable determination of coreceptor use status before the initiation of treatment.
The adapted ViroLogic PhenoSense coreceptor assay was used in the present study. The nonamplifiable rate for the assay was 24% in our samples. Nonamplified samples were more likely to have lower viral loads and not be clade B, although differences were numerically modest. However, both low-viral load and non-clade B samples were commonly successfully amplified and contributed to the main data set. Because these samples were previously frozen at Ϫ70ЊC, thawed for aliquoting, and refrozen for shipping, the integrity of the RNA may have been affected, along with the recovery of the 2.5-kb env gene sequence required for the assay. Freeze/thaw/freeze procedures at our site have not been observed to affect the extraction of the 2.2-kb pol gene sequences (A.W., unpublished data).
Reports of the clinical use of CCR5 antagonist agents have suggested that these agents do not result in significant HIV-1 RNA decreases in the presence of detectable proportions of X4 viruses, although decreases in the number of R5 viruses may be seen [8] . In the absence of predictive laboratory markers, these data would support the need for the consideration of routine screening for R5X4 or X4 viruses in individuals who plan to receive CCR5 antagonists. Further data are required to establish whether screening would be as critical in the setting of combination use of these agents with approved antiretroviral agents, because these agents have been shown to effectively and preferentially suppress X4 virus in vivo [11, 12] . Viral clade or pol gene sequence do not appear to be associated with chemokine coreceptor use; hence, screening for these viral characteristics is not necessary.
The association with the NK cell count-higher numbers being associated with a greater chance of having CCR5-using virus-has not, to our knowledge, been reported previously. The mechanism for this association is not clear, but it may relate to the role played by NK cells as an important source of CC chemokines [13] , although their role in the production of the ligand of CXCR4, stromal cell-derived factor 1, is not clear. HIV has recently been reported to persistently infect NK cells, and HIV viremia has been observed to up-regulate CCR5 expression on NK cells [14, 15] . Because our patients had detectable HIV-1 RNA, this up-regulation effect was likely to be present, making a "predator-prey" explanation for this observation a possibility. An inverse correlation between the level of viremia and the ability of NK cells and NK-derived supernatants to suppress virus replication has been reported and has been suggested to be related to the production of CC chemokines [16] . These data are also in keeping with our data: a lower NK cell count and higher viral load were both associated with a greater risk of CXCR4-using virus being detected.
In summary, chemokine coreceptor tropism of HIV is associated with CD4 cell counts, HIV-1 RNA levels, and NK cell counts. The presence of dual X4R5 or mixed populations or of X4-using virus may be seen at all CD4 cell counts and viral loads but is more common at lower CD4 cell counts and higher viral loads. Screening for chemokine coreceptor use may be necessary before the initiation of treatment with chemokine coreceptor antagonists.
